A case of recipient bed melt and wound dehiscence after penetrating keratoplasty and subconjunctival injection of bevacizumab

Cornea

Volumn 31, Issue 11, 2012, Pages 1342-1343

  Bhasin, Purendra ^a   Gujar, Prateek ^a   Bhasin, Priyamvada ^a  

^a Ratan Jyoti Netralaya   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOXYMETHYLCELLULOSE; CYANOACRYLATE; MOXIFLOXACIN; PREDNISOLONE ACETATE;

ADULT; ANTERIOR EYE CHAMBER; ARTICLE; ASTIGMATISM; BANDAGE CONTACT LENS; BLURRED VISION; CASE REPORT; CORNEA DISEASE; CORNEA EDEMA; CORNEA NEOVASCULARIZATION; DRUG SAFETY; EPITHELIZATION; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HUMAN; ISCHEMIA; LIMBAL ISCHEMIA; MALE; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; RECIPIENT BED MELT; SCAR FORMATION; SLIT LAMP; SUTURE REMOVAL; VISUAL IMPAIRMENT; WOUND DEHISCENCE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONJUNCTIVA; CORNEAL ULCER; CYANOACRYLATES; GRAFT SURVIVAL; HUMANS; INJECTIONS, INTRAOCULAR; KERATOPLASTY, PENETRATING; MALE; POSTOPERATIVE COMPLICATIONS; SURGICAL WOUND DEHISCENCE; TISSUE ADHESIVES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867395958     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318245c044     Document Type: Article

References (16)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
2. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18:502-508.
3. Hill JC, Maske R. An animal model for corneal graft rejection in highrisk keratoplasty. Transplantation. 1988;46:26-30.
4. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982.
5. O'Neill EC, Qin Q, Van Bergen NJ, et al. Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci. 2010;51:6524-6532.
6. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
7. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
8. Galor A, Yoo SH. Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging. 2010;41:1-3.
9. Asahara T, Bauters C, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995;92(9 suppl):II365-II371.
10. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549-580.
11. Polling EA, Legesse-Miller A, Haley EM, et al. Regulating the angiogenic balance in tissues. Cell Cycle. 2008;7:2056-2070.
12. Wilgus TA, Ferreira AM, Oberyszyn TM, et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88:579-590.
13. Yu CQ, Zhang M, Matis KI, et al. Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci. 2008;49:3870-3878.
14. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical Bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009;127: 381-389.
15. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-1795.
16. Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009;66:999-1013.